Skip to main content

Table 1 % Change antioxidant gene expression in healthy volunteers following O3 exposure

From: A proof-of-concept clinical study examining the NRF2 activator sulforaphane against neutrophilic airway inflammation

 

Placebo

SFN

*p value

Nasal Epithelial Cells

 GSTM1

58.74 ± 57.07

49.99 ± 41.76

0.9375

 HO-1

2.041 ± 24.97

−6.06 ± 16.69

0.9097

 NQO-1

27.65 ± 44.88

39.35 ± 41.57

0.9097

 NRF-2

2.521 ± 17.42

0.9522 ± 18.52

0.9097

Peripheral Blood

 GSTM1

26.29 ± 44.12

−14.11 ± 20.05

>0.9999

 HO-1

−5.42 ± 13.93

−7.61 ± 17.17

0.9453

 NQO-1

13.87 ± 43.43

−18.18 ± 26.59

0.9375

 NRF-2

22.8 ± 27.20

−12.59 ± 10.89

0.6406

  1. Data are shown as mean ± SEM
  2. Changes in GSTM1 expression were performed only on GSTM1 sufficient subjects. For all genes, N = 6–14
  3. *Comparisons between Placebo and SFN groups were carried out using paired Wilcoxon-Signed rank tests
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us